Methods of manufacture of therapeutic products comprising vitalized placental dispersions

Abstract

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

1 - 36 . (canceled) 
     
     
         37 . A method of manufacturing a therapeutic placental product comprising:
 a) obtaining a first placental tissue;   b) obtaining placental cells from the first placental tissue;   c) obtaining a second placental tissue;   d) disrupting the second placental tissue to form a dispersion comprising placental factors; and   e) combining the placental cells and the placental dispersion to form the placental product, wherein the placental dispersion is a homogenate.   
     
     
         38 . The method of  claim 37 , wherein the first placental tissue is autologous to the second placental tissue and wherein the first placental tissue and the second placental tissue are chorionic tissue. 
     
     
         39 . The method of  claim 38 , wherein the second placental tissue is derived from the fist placental tissue after the step of obtaining the placental cells. 
     
     
         40 . The method of  claim 39 , wherein the step of obtaining the placental cells comprises exposing the first placental tissue to a protease, optionally wherein the protease is a collagenase. 
     
     
         41 . The method of  claim 40 , wherein the protease exposing step has a duration of about 30 minutes or less. 
     
     
         42 . The method of  claim 40 , wherein the protease exposing step releases less than about 10% of the maximum number of releasable placental cells. 
     
     
         43 . The method of  claim 38 , wherein the chorionic tissue is depleted of trophoblasts. 
     
     
         44 . The method of  claim 43 , wherein the trophoblasts are depleted by dissection and dispase treatment. 
     
     
         45 . The method of  claim 37 , wherein the placental product comprises one or more members selected from the group consisting of extracellular matrix proteins; protease inhibitors; angiogenic factors; and placental factors which promotes the migration of epithelial cells into a wound. 
     
     
         46 . The method of  claim 37 , wherein the placental product comprises one or more protease inhibitors selected from the group consisting of matrix metalloproteinases (TIMPs), alpha-2 macroglobulin, and thrombospondins. 
     
     
         47 . The method of  claim 37 , wherein the placental product comprises one or more angiogenic factors selected from the group consisting of VEGF and bFGF. 
     
     
         48 . The method of  claim 37 , wherein the placental product comprises one or more factors which promote the migration of epithelial cells into a wound selected from the group consisting of HGF and KGF. 
     
     
         49 . The method of  claim 37 , wherein the placental cells are selected from the group consisting of MSCs, ESCs, placenta-derived mesenchymal progenitor cells, placental mesenchymal stem cells fibroblasts, epithelial cells, placental mesenchymal cells, and macrophages. 
     
     
         50 . The method of  claim 49 , wherein the placental cells are present at a concentration of at least about 20,000 per ml of placental product. 
     
     
         51 . The method of  claim 37 , wherein at least one of the placental cells or the placental dispersion is cryopreserved. 
     
     
         52 . The method of  claim 37 , wherein the placental cells are cryopreserved before combining with the placental dispersion, and wherein the placental dispersion is optionally cryopreserved before combining with the placental cells. 
     
     
         53 . The method of  claim 37 , wherein the placental cells comprise stromal cells and the placental cells are cryopreserved. 
     
     
         54 . The method of  claim 39 , wherein:
 a. the step of obtaining the placental cells comprises exposing the first placental tissue to a protease;   b. the protease exposing step is of about 30 minutes or less duration;   c. the protease exposing step releases less than about 10% of the maximum number of releasable placental cells;   d. the chorionic tissue is depleted of trophoblasts;   e. the placental product comprises one or more protease inhibitors selected from the group consisting of matrix metalloproteinases (TIMPs), alpha-2 macroglobulin, and thrombospondins;   f. placental product comprises one or more of VEGF and bFGF;   g. the placental product comprises one or more of HGF and KGF;   h. the placental cells comprise MSCs and cells selected from the group consisting of ESCs, placenta-derived mesenchymal progenitor cells, placental mesenchymal stem cells fibroblasts, epithelial cells, placental mesenchymal cells, and macrophages;   i. the placental cells are present at a concentration of at least about 20,000 per ml of placental product; and   j. at least one of the placental cells and the placental dispersion is cryopreserved.   
     
     
         55 . A method of treating a tissue injury comprising administering to a subject in need thereof a therapeutic placental product made by the method of  claim 37 .